EGFR Inhibitor-associated Rash research hub

TAR-0520 Gel in EGFR Inhibitor-induced Folliculitis

This study is testing a new gel (TAR-0520) to see if it can prevent a common skin rash called folliculitis. This rash can happen in people with bowel cancer who are receiving certain anti-cancer treatments (cetuximab or panitumumab). It aims to confirm the gel's safety and explore how well it works.